Pharmacokinetics and Tolerability of CKD-348 in Healthy Volunteers

Phase 1, randomised, open-label trial of telmisartan, Levamlodipine, rosuvastatin and ezetimibe in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Jan 2021; status: completed.